Dubai, March 16th 2015 Genpharm and Genzyme extend their on-going collaboration in Middle East and North Africa (MENA) region in the field of Multiple Sclerosis, with the addition of Alemtuzumab.
Lemtrada (Alemtuzumab) is an FDA approved Disease Modifying Therapy for the treatment of Relapsing Remitting Multiple Sclerosis; it has a unique dosing and administration schedule of two annual treatment courses. The first treatment course is administered via intravenous infusion on five consecutive days, and the second course is administered on three consecutive days, 12 months later. MS is a chronic, inflammatory, autoimmune disease of the central nervous system that disrupts communication between the brain and other parts of the body. It is among the most common causes of neurological disability in young adults and occurs at least twice as frequently in women as in men. For most people with MS, episodes of worsening function (relapses) are initially followed by recovery periods (remissions). Over time, recovery periods may be incomplete, leading to progressive decline.
The FDA approval of Lemtrada is based on two pivotal randomized Phase III open-label rater-blinded studies comparing treatment with Lemtrada to Rebif® (high-dose subcutaneous interferon beta-1a) in patients with relapsing remitting MS who were either new to treatment (CARE-MS I) or who had relapsed while on prior therapy (CARE-MS II).
Lemtrada was approved by the European Commission (EC) for use in the treatment of adult patients with relapsing remitting multiple sclerosis with active disease defined by clinical or imaging features.
For full prescribing information and more information about Lemtrada please visit: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003718/WC500150521.pdf
For further information related to Lemtrada and its availability in your country of residence, please contact us at: Phone: +971 4 4227010 or Genzyme MENA at + 971 4 4227010
Alemtuzumab ( Lemtrada ) is not registered in any of the Middle East and North Africa countries.